Skip to main content

Table 2 Laboratory and ultrasound data of our patients before treatment and 3 and 12 months after the end of treatment

From: Assessment of hepatic fibrosis, portal hemodynamic changes, and disease severity in patients with HCV-related liver cirrhosis after sustained virologic response to direct-acting antiviral drugs (DAAs)

Item

Baseline (before treatment)

n = 100”

3 months After treatment

n = 100”

12 months after treatment

n = 100”

P value

Hemoglobin %

12.9 ± 2.57

12.25 ± 2.17

P1 = 0.275

11.77 ± 2.04

P2 < 0.02*

P < 0.02*

P3 = 0.208

Red blood cells

4.7 ± 0.60

4.27 ± 0.54

P1 = 0.483

4.29 ± 0.713

P2 = 0.628

P = 0.087

P3 = 0.682

White blood cells

6.55 ± 0.35

6.18 ± 1.27

P2 = 0.492

3.94 ± 2.63

P2 < 0.001**

P < 0.001**

P3 < 0.001**

Platelets

155.5 ± 63.34

156.41 ± 69.46

P1 = 0.372

159.80 ± 72.56

P2 = 0.435

P = 0.106

P3 = 0.468

Urea

34.74 ± 7.64

34.82 ± 8.43

P1 = 0.573

34.93 ± 9.81

P2 = 0.708

P = 0.622

P3 = 0.429

Creatinine

0.94 ± 0.20

0.99 ± 0.41

P1 = 0.349

1.02 ± 0.14

P2 = 0.617

P = 0.103

P3 = 0.669

AFP

9.31 ± 1.22

5.21 ± 1.17

P1 < 0.02*

3.85 ± 1.09

P2 < 0.001**

P < 0.01*

P3 < 0.03*

AST

63.36 ± 14.22

42.45 ± 10.46

P1 < 0.001**

29.15 ± 6.33

P2 < 0.000***

P < 0.001**

P3 < 0.000***

ALT

59.89 ± 15.24

38.74 ± 11.24

P1 < 0.001**

23.84 ± 8.64

P2 < 0.000***

P < 0.001**

P3 < 0.001**

S. Bilirubin

0.932 ± 0.51

0.918 ± 0.34

P1 = 0.573

0.858 ± 0.16

P2 = 0.508

P = 0.482

P3 = 0.337

S. Albumin

3.67 ± 0.57

3.78 ± 0.48

P1 = 0.241

3.95 ± 0.47

P2 < 0.01*

P < 0.01*

P3 < 0.03*

INR

1.19 ± 0.19

1.17 ± 0.14

P1 = 0.248

1.14 ± 0.15

P2 < 0.02*

P < 0.04*

P3 < 0.03*

Ascites

9 (9%)

13 (13%)

1 (1%)

P < 0.001** $

  1. Data expressed as mean ± SD
  2. ALT Alanine transaminase, AST Aspartate transaminase, INR International normalization ratio, AFP Alpha fetoprotein
  3. P value was calculated using repeated measures ANOVA
  4. *Significant difference P < 0.05
  5. **Moderate significant difference P < 0.001
  6. ***Highly significant difference P < 0.000
  7. P: comparison between baseline and 3 and 12 months after the end of treatment
  8. P1: comparison between baseline and 3 months after the end of treatment
  9. P2: comparison between baseline and 12 months after the end of treatment
  10. P3: comparison between 3 and 12 months after the end of treatment
  11. $P value using chi-square test